EUCTR2006-005597-43-GBActive, not recruitingPhase 1
Topical Retinoids and Diabetic Neuropathic Ulceration - Retinoid Study
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- niversity of Birmingham
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •1.Type 1 or Type 2 Diabetes as defined by the World Health Organisation classification.
- •2.Age between 18-70 years.
- •3.Women of child bearing potential must be using an acceptable method of contraception to prevent pregnancy when they are enrolled in the study and must agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
- •4.Must meet the specified criteria for diabetic neuropathy and have no risk factors for other causes of neuropathy
- •5.Willingness to sign the Centre for Research Ethics Committee (COREC) approved informed consent form.
- •6.The presence of microalbuminurea and/or retinopathy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1.Nursing mothers, pregnant women (excluded by a negative pregnancy test).
- •2.Patients with a history of drug or alcohol dependence within the last 5 years.
- •3.Patients with severe systemic disease other than diabetes which has a recognized complication of neuropathy.
- •4.Patients with a history of previous kidney, pancreas or cardiac transplantation.
- •5.Serious or unstable medical or psychological state that may interfere with study participation.
- •6.Patients having taken part in another investigational drug study within the last three months.
- •7.Patients who refuse to sign the informed consent form.
- •8.Patients with pre-existing generalized skin conditions which might affect skin structure or function such as eczema, psoriasis.
- •9.Patients who are on long term steroid or immunosuppressive therapy.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Pharmacological intervention on diabetic retinopathy with PGF - LATANO-2Diabetic retinopathyEUCTR2010-022433-29-DKAarhus University Hospital, Department of Ophthalmology50
Not yet recruiting
Unknown
Occurrence of Peripheral neuropathy in patients of Type 2 DiabetesCTRI/2024/03/064317Ayurswasthya Yojana, Centre of excellence Scheme, Ministry of Ayush, Govt of India
Active, not recruiting
Phase 1
Taurine and Painful Diabetic NeuropathyEUCTR2005-004196-37-GBniversity of Birmingham, Research & Enterprise Services180
Completed
Not Applicable
Taurine and painful diabetic neuropathyNervous System DiseasesDiabetic neuropathyISRCTN49416618niversity of Birmingham (UK)180
Active, not recruiting
Phase 1
Examination of day-night cycle and the effect of medication with the neurohormone melatonin on visual functions in patients with diabetic retinopathyDiabetic Retinopathy and Sleep disorderMedDRA version: 20.1Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersEUCTR2015-003955-23-DKDept. of Ophthalmology, Rigshospitalet – Glostrup32